Sugi Predict

Sugi Predict / Compounds / SCHEMBL15516277

SCHEMBL15516277

SCHEMBL15516277

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@@H]1CCCN1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 11/20 0.63
▸ SRC P12931 11/20 0.63
▸ TEK Q02763 8/20 0.63
▸ BTK Q06187 11/20 0.62
▸ FYN P06241 2/20 0.62
▸ LYN P07948 2/20 0.62
▸ HCK P08631 2/20 0.62
▸ YES1 P07947 1/20 0.62
▸ FGR P09769 1/20 0.62
▸ TEC P42680 1/20 0.62
▸ TXK P42681 1/20 0.62
▸ BLK P51451 1/20 0.62
▸ BMX P51813 1/20 0.62
▸ ERBB4 Q15303 1/20 0.62
▸ KDR P35968 3/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ RGS12 O14924 1/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ GMNN O75496 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15516278 1.00 LCK (0.63) LCKSRCTEKBTKFYN
SCHEMBL15515996 0.88 BTK (0.58) LCKSRCTEKBTKFYN
SCHEMBL13860356 0.81 EGFR (0.65) LCKSRCBTKFYNLYN
SCHEMBL13860354 0.81 EGFR (0.65) LCKSRCBTKFYNLYN
SCHEMBL16769953 0.80 BTK (0.47) LCKSRCTEKBTKFYN
SCHEMBL16769926 0.80 BTK (0.47) LCKSRCTEKBTKFYN
SCHEMBL15916520 0.80 LCK (0.62) LCKSRCTEKBTKFYN
SCHEMBL15916523 0.80 LCK (0.62) LCKSRCTEKBTKFYN
SCHEMBL16769951 0.79 BTK (0.43) LCKSRCTEKBTKFYN
SCHEMBL7006747 0.78 SRC (1.00) LCKSRCTEKBTKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9572811-B2 Treatment of dry eye PRINCIPIA BIOPHARMA INC. (US) 2017-02-21 — — US disclosed
EP-2710005-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2016-10-05 — — EP disclosed
CN-103534258-B Tyrosine kinase inhibitor 普林斯匹亚生物制药公司 2016-09-14 — — CN disclosed
US-9376438-B2 Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2016-06-28 — — US disclosed
US-9376438-B2 Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2016-06-28 — — US disclosed
US-9376438-B2 Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2016-06-28 — — US disclosed
US-20150353557-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2015-12-10 — — US disclosed
US-20150353562-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2015-12-10 — — US disclosed
US-9090621-B2 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2015-07-28 — — US disclosed
US-20150182530-A1 TREATMENT OF DRY EYE PRINCIPIA BIOPHARMA INC. (US) 2015-07-02 — — US disclosed
US-20140309223-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-10-16 — — US disclosed
US-20140303161-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. 2014-10-09 — — US disclosed
US-20140303190-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-10-09 — — US disclosed
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-08-07 — — US disclosed
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-08-07 — — US disclosed
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-08-07 — — US disclosed
US-8759358-B1 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2014-06-24 — — US disclosed
US-8673925-B1 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2014-03-18 — — US disclosed
WO-2014022569-A1 TREATMENT OF DRY EYE PRINCIPIA BIOPHARMA INC. (US) 2014-02-06 — — WO disclosed
CN-103534258-A Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC 2014-01-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353557-A1 TYROSINE KINASE INHIBITORS BMX, ITK, BLK LCK 10/4885SRC 18/4885TEK 440/4885
US-20140303161-A1 TYROSINE KINASE INHIBITORS BMX, ITK, BLK LCK 10/4885SRC 18/4885TEK 440/4885
US-20150353562-A1 TYROSINE KINASE INHIBITORS BMX, ITK, BLK LCK 10/4885SRC 18/4885TEK 440/4885
US-20140303190-A1 TYROSINE KINASE INHIBITORS BMX, ITK, BLK LCK 10/4885SRC 18/4885TEK 440/4885
US-20140221398-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS BMX, BLK, TEC LCK 14/4885SRC 25/4885TEK 482/4885
US-20140309223-A1 TYROSINE KINASE INHIBITORS BMX, ITK, BLK LCK 10/4885SRC 18/4885TEK 440/4885
US-20150182530-A1 TREATMENT OF DRY EYE BTK, SYK, LYN LCK 4/4885SRC 8/4885TEK 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback